24-Jul-2019 - Lonza Group Ltd

Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC

Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Building on 12 years of experience in the exacting bioconjugation space, Lonza’s expansion will meet the development and manufacturing needs of pharma and biotech companies developing a new generation of therapies.

Lonza’s Visp site completed a successful FDA inspection for commercial manufacture of a recently approved ADC, the third to be commercialized from the bioconjugation facility. The existing capacity at the Visp facility will cover the current needs for production of this fast-tracked therapy.

Facts, background information, dossiers
  • Lonza
  • bioconjugation
  • bioconjugation facilities
More about Lonza
  • News

    CEO Marc Funk leaves Lonza

    Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found. Marc will ... more

    Carve-out of Lonza Specialty Ingredients will help segment to become a global leader in microbial control

    Lonza Group announced its intention to proceed with a carve-out of its Specialty Ingredients segment (LSI). The decision will see the LSI business under independent management, with increased control over its operations and costs. The segment will remain fully owned by Lonza. The company ha ... more

    Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome

    Chr. Hansen Holding A/S and Lonza AG have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joi ... more

  • Companies

    Lonza Cologne GmbH

    About Lonza Cologne GmbH Lonza Cologne GmbH offers products for various everyday uses, such as disinfectants and detergents in hospitals or pool and spa areas, in pesticides against snails (metaldehyde), in sports and energy drinks (vitamin B3, L-Carnitine) or in body lotions as emulsifyin ... more

    Lonza Group Ltd

    Lonza continues to leverage its core strengths in innovation, technology, and regulatory expertise while capturing cross-divisional synergies in manufacturing, research, and sales. By clicking the Factsheet will find a detailed breakdown of our management committees, business divisions, gro ... more

    Lonza Milano, S.r.l.

    more